CRISPR-based techniques allow the reconstruction of the “family tree” of the cells that compose an animal’s body by marking them with a pattern of deletions and insertions. This kind of barcoding has already helped trace embryo growth and organoid development and is shedding light on essential oncology questions by catching cancer in the act. Read how “Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts” in this Science paper and the news from Whitehead Institute.
What’s the right way to regulate edited-plants? The question still waits for an answer in Brussels, and debate goes on in Europe.
According to Reuters, France backs non-GMO regulation for crop gene-editing in the EU. Gene editing of crops and livestock may soon be permitted in England, says the Guardian. Parliamentary commissions divided on new breeding techniques, media report in Italy. For a comparative viewpoint of regulatory frameworks globally, see the recent “Genome editing for crop improvement” by All European Academies.
A paper published in Nature by CRISPR innovator David Liu and a giant in medical genetics, Francis Collins, raises great hopes for treating a rare, devastating pediatric disease causing premature-aging (Hutchinson-Gilford progeria syndrome). “The outcome is incredible,” according to gene-therapy researcher Guangping Gao. “Dance on the lab bench” amazing, according to editing pioneer Fyodor Urnov. Let’s be clear: the CRISPR variant called a base-editor has helped only progeria mice so far, but results are beyond anyone’s wildest expectations. One injection is enough to fix the single-letter mutation in several tissues, doubling mice’s lifespan. To learn more, see David Liu’s tweets and the NIH Director’s Blog.
The sickle cell trial in NEJM; Covid19 test using smartphone cameras in Cell; all-male mosquitoes in Nature Biotechnology; CRISPR golden rice in Nature Communications; CRISPR meets cancer therapy in Science; mitochondrial editing in Nature; first in vivo treatment in Nature news; resistant bananas in Nature news; very fast CRISPR in Science; body parts regrowing in Science.
According to the survey conducted by Pew Research Center in 20 countries, people are positive about gene-editing if used to treat illnesses a baby would have at birth (support is particularly strong in Spain). People are also generally in favor of using human gene editing to reduce the risk of future health problems, but less so. India is the only country where the majority says the possibility of using human gene editing to make a baby more intelligent is also acceptable. See more data here.
Here you can watch le Nobel Lectures by Emmanuelle Charpentier and Jennifer Doudna. Emmanuelle is very focused and très, très chic, oui. Jennifer is generous with credits to colleagues and willing to represent the public conscience of genomic editing. The thing I liked most is the reference to CRISPR-Casɸ: a hypercompact genome editor found in huge phages. Probably it evolved to target the genes of competing phages inside bacterial hosts.Continue reading
Traditionally the Nobel Laureates travel to Stockholm to receive their prizes. This year the prizes are coming to them. On 7 December, 19.00 CET, the diploma and medal will be presented to Emmanuelle Charpentier at the Swedish Ambassador’s Residence in Berlin. On 8 December, 16.00 PST, it’s Jennifer Doudna’s turn at the Residence of Barbro Osher, Honorary Consul General in San Francisco. Also on 8 December, 11-13 CET, we can watch online the Academy’s official Nobel Lectures 2020: For the development of a method for genome editing, by Emmanuelle Charpentier, and The Chemistry of CRISPR: Editing the Code of Life, by Jennifer A. Doudna. Full programme here.
December is time for rankings and forecasts. Let’s start with STAT News celebrating young talents who could become the next generation of scientific superstars. Three CRISPR researchers appear among STAT wunderkinds. As a postdoc at the Broad Institute, Andrew Anzalone helped make a key advance by developing prime editing, where the same RNA molecule specifies the target and the desired edit. Jennifer Hamilton, from Berkeley, works on solving one of the major hurdles of CRISPR-based therapies: delivering the genome editor to the desired cells. Cameron Myhrvold, has since worked at the Broad Institute on developing CRISPR-based diagnostics such as CARMEN and is about to start his own lab at Princeton.